REFERENCES
1. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761-7.
3. Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res 2013;161:1-14.
4. Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol 2018;4:569-79.
5. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 2012;5:868-77.
6. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-33.
8. Rohatgi RK, Sugrue A, Bos JM, et al. Contemporary outcomes in patients with long QT syndrome. J Am Coll Cardiol 2017;70:453-62.
9. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;10:1932-63.
10. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol 2018;72:e91-e220.
11. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109:1826-33.
12. Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J 2022;43:2096-102.
13. Dusi V, Pugliese L, De Ferrari GM, et al. Left cardiac sympathetic denervation for long QT Syndrome: 50 Years’ experience provides guidance for management. JACC Clin Electrophysiol 2022;8:281-94.
14. Johnson JN, Ackerman MJ. Competitive sports participation in athletes with congenital long QT syndrome. JAMA 2012;308:764-5.
15. Christensen KD, Bell M, Zawatsky CLB, et al. Precision population medicine in primary care: the sanford chip experience. Front Genet 2021;12:626845.
16. Natasha Petry, Baye J, Aifaoui A, et al. Implementation of wide-scale pharmacogenetic testing in primary care. Pharmacogenomics 2019;20:903-13.
17. Sorita A, Bos JM, Morlan BW, Tarrell RF, Ackerman MJ, Caraballo PJ. Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes. J Am Med Inform Assoc 2015;22:e21-7.
18. Trinkley KE, Pell JM, Martinez DD, Maude NR, Hale G, Rosenberg MA. Assessing prescriber behavior with a clinical decision support tool to prevent drug-induced long QT syndrome. Appl Clin Inform 2021;12:190-7.
19. Hymel N, Davies M. Evidence-based antiemetic decision tool for management of postoperative nausea and vomiting in patients at high risk of QT prolongation and patients receiving neurotransmitter-modulating medications. AANA J 2020;88:312-8.
20. Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 2016;67:1639-50.
21. Grissinger M. Selected medication safety risks that can easily fall off the radar screen. P T 2018;43:521-67.
22. Miller DT, Lee K, Chung WK, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23:1381-90.
